background
commun
acquir
virus
crv
may
caus
sever
diseas
cancer
patient
thu
effort
made
diagnos
crv
rapidli
manag
crv
infect
accordingli
method
panel
clinician
infecti
diseas
work
parti
german
societi
haematolog
medic
oncolog
conven
assess
avail
literatur
provid
recommend
manag
crv
infect
includ
influenza
respiratori
syncyti
viru
parainfluenza
viru
human
metapneumoviru
adenoviru
result
crv
infect
cancer
patient
may
lead
pneumonia
approxim
case
associ
mortal
around
diagnosi
crv
infect
combin
nasalthroat
swab
washesaspir
give
best
result
nucleic
acid
amplif
basedtechniqu
nat
use
detect
pathogen
hand
hygien
contact
isol
face
mask
shown
benefit
gener
infect
manag
causal
treatment
given
influenza
use
neuraminidas
inhibitor
respiratori
syncyti
viru
use
ribavirin
addit
intraven
immunoglobulin
ribavirin
also
use
treat
parainfluenza
viru
human
metapneumoviru
data
inconclus
set
cidofovir
use
treat
adenoviru
pneumon
conclus
crv
infect
may
pose
vital
threat
patient
underli
malign
guidelin
provid
inform
diagnosi
treatment
improv
outcom
import
commun
acquir
respiratori
viru
crv
infect
increasingli
recognis
crv
respons
respiratori
infect
usual
present
common
cold
immunocompet
individu
may
lifethreaten
immunocompromis
host
usual
orthomyxovirida
influenza
b
c
paramyxovirida
includ
parainfluenza
piv
respiratori
syncyti
viru
b
rsv
human
metapneumoviru
hmpv
coronavirida
picornavirida
includ
differ
serotyp
rhinoviru
enteroviru
adenovirida
polyomaviru
type
bocaviru
regard
potenti
caus
crv
infect
guidelin
intend
give
haematologist
oncologist
broad
overview
regard
clinic
relev
diagnosi
crv
infect
manag
cancer
patient
affect
crv
detail
inform
respect
virus
includ
emerg
resist
scope
guidelin
data
topic
origin
patient
follow
allogen
stem
cell
transplant
allosct
know
littl
crv
infect
cancer
patient
outsid
set
allosct
howev
recent
year
increas
evid
gather
cancer
patient
reveal
clinic
relev
crv
infect
nontranspl
patient
therefor
guidelin
discuss
crv
infect
cancer
patient
ongo
relev
immunosuppress
left
treat
physician
assess
degre
relev
immunosuppress
individu
patient
guidelin
develop
panel
infecti
diseas
work
parti
agiho
german
societi
haematolog
medic
oncolog
includ
expert
certifi
intern
medicin
haematologyoncolog
infecti
diseas
microbiologyvirolog
radiolog
one
medic
student
first
predefin
topic
deliv
design
coordin
mvlt
particip
panel
form
subgroup
data
extract
tabul
systemat
literatur
search
subgroup
member
revis
sever
step
member
panel
basi
emailbas
discuss
process
facetofac
meet
final
preliminari
recommend
panel
discuss
revis
approv
agiho
assembl
may
first
literatur
search
perform
crv
immunosuppress
use
term
viru
immunocompromis
exampl
adenoviru
immunocompromis
search
perform
adenoviru
bocaviru
coronaviru
enteroviru
hmpv
influenza
piv
parechoviru
rsv
rhinoviru
refer
screen
subgroup
member
relev
articl
retriev
full
paper
wherev
applic
addit
paper
identifi
refer
list
treat
describ
crv
caus
respiratori
tract
infect
divid
upper
respiratori
tract
infect
urti
influenzalik
ill
ili
lower
respiratori
tract
infectionpneumonia
lrti
commonli
urti
assum
patient
new
onset
symptom
includ
least
one
cough
coryza
sore
throat
short
breath
deem
due
infect
treat
physician
lrti
requir
clinic
radiolog
evid
pneumonia
ili
diagnos
patient
sudden
onset
new
symptom
includ
least
one
fever
feverish
malais
headach
myalgia
least
one
respiratori
symptom
cough
sore
throat
short
breath
certain
viral
origin
detect
viru
respiratori
sampl
like
swab
nasopharyng
aspir
bronchoalveolar
lavag
fluid
requir
note
surveil
studi
show
patient
asymptomat
still
shed
viru
reason
author
distinguish
respiratori
infect
detect
viru
independ
symptom
respiratori
infect
diseas
detect
viru
respect
symptom
howev
purpos
guidelin
omit
distinct
defin
urti
lrti
ili
describ
crv
like
influenza
rsv
season
infect
occur
winter
month
other
like
rhinoviru
parainfluenza
independ
season
thu
appropri
diagnost
workup
clinic
manag
warrant
patient
present
typic
symptom
regardless
time
year
may
expect
consid
natur
diseas
crv
frequent
caus
outbreak
health
care
set
importantli
outbreak
may
also
occur
outpati
set
emphasis
need
awar
period
cancer
treatment
gener
viral
urti
cancer
patient
impact
clinic
cours
patient
symptomat
degre
frequent
requir
postpon
chemotherapi
howev
critic
tabl
grade
evid
suggest
escmid
strongli
support
recommend
use
b
moder
support
recommend
use
c
margin
support
recommend
use
support
recommend
use
qualiti
evid
interventionsdlevel
evid
least
one
properli
design
random
control
trial
ii
evid
least
one
welldesign
clinic
trial
without
random
cohortor
casecontrol
analyt
studi
prefer
one
centr
multipl
time
seri
dramat
result
uncontrol
experi
least
one
welldesign
prospect
singlecentr
crosssect
cohort
studi
properli
design
retrospect
multicentr
crosssect
cohort
studi
casecontrol
studi
iii
evid
opinion
respect
author
base
clinic
experi
descript
case
studi
report
expert
committe
ill
mortal
due
viral
urti
rare
contrast
patient
die
suffer
lrti
thu
pose
biggest
threat
cancer
patient
rate
lrti
mortal
differ
amongst
respect
crv
exact
estim
hamper
fact
fatal
case
probabl
overreport
tri
deduc
reliabl
inform
lrti
mortal
literatur
variou
crv
influenza
appear
high
rate
lrti
approxim
associ
mortal
rate
approxim
rsv
appear
least
danger
rate
lrti
approxim
associ
mortal
rate
howev
kept
mind
data
regard
rsv
origin
sctrecipi
littl
known
regard
patient
form
malign
hand
sever
report
outbreak
gener
haematologyoncolog
unit
show
signific
diseas
burden
even
patient
undergo
stem
cell
transplant
regard
hmpv
piv
exact
inform
clinic
relev
even
difficult
obtain
howev
although
virus
may
caus
asymptomat
infect
avail
evid
suggest
similar
overal
rate
lrti
mortal
compar
influenza
rsv
contrast
despit
case
report
fatal
outcom
infect
rhinoviru
coronaviru
virus
well
bocaviru
appear
rare
caus
lrti
danger
patient
coinfect
pathogen
herpesvirida
like
herp
simplex
viru
human
herp
viru
cytomegaloviru
varicella
zoster
epsteinebarr
viru
well
polyomavirus
parechovirus
usual
caus
crv
infect
pneumonia
due
reactiv
herpesvirida
sever
immunocompromis
patient
infect
crv
thu
cover
guidelin
crv
infect
coinfect
bacteria
fungi
even
virus
appear
occur
approxim
patient
play
vital
role
regard
outcom
patient
sinc
patient
bacteri
fungal
superinfect
dramat
higher
mortal
rate
viral
infect
therefor
possibl
coor
superinfect
consid
manag
cancer
patient
crv
addit
lrti
bacteri
fungal
superinfect
risk
factor
advers
outcom
includ
haematolog
malign
sever
immunosuppress
steroid
use
graft
versu
host
diseas
cytopenia
low
immunoglobulin
epidemiolog
adenovirus
somewhat
differ
crv
often
sourc
infect
childhood
infect
children
year
reactiv
well
new
infect
describ
caus
diseas
crv
like
rsv
influenza
adenovirus
caus
varieti
symptom
conjunct
haemorrhag
cystiti
gastroenter
urti
immunocompet
patient
hepat
coliti
nephriti
meningoenceph
lrti
immunocompromis
host
adult
allosct
recipi
dnaemia
occur
symptomat
diseas
adenoviru
much
less
common
tcell
suppress
predomin
risk
factor
coinfect
import
risk
factor
sever
ill
cancer
patient
present
symptom
consist
crv
infect
diagnos
use
materi
respiratori
tract
tabl
serolog
use
detect
ongo
crv
infect
thu
recommend
iii
regard
materi
use
microbiolog
diagnosi
varieti
approach
use
variou
centr
gener
rule
close
collabor
local
microbiolog
laboratori
highli
recommend
may
determin
materi
use
prefer
sinc
commerci
avail
test
kit
licens
specif
materi
exampl
test
viral
antigen
usual
requir
thorough
sampl
like
combin
nasalthroat
swab
test
viral
nucleic
acid
often
perform
reliabl
gargl
alon
therefor
essenti
clinician
awar
test
use
respect
laboratori
overal
evid
literatur
best
combin
nasalthroat
swab
nasopharyng
aspir
iit
tabl
best
evid
reliabl
detect
crv
present
respiratori
sampl
exist
nucleic
acid
amplif
basedtechniqu
nat
like
pcr
therefor
use
nat
highli
recommend
ii
tabl
method
involv
detect
antigen
appear
second
best
immunosuppress
cancer
patient
c
ii
also
cultur
method
commonli
use
anymor
recommend
gener
diagnosi
essenti
individu
case
known
viru
detect
result
pcranalysi
inconclus
ii
era
multiplextest
kit
difficult
make
definit
recommend
regard
virus
look
absenc
reliabl
data
regard
question
panel
feel
wise
search
influenza
rsv
piv
virus
current
preval
local
environ
immunosuppress
cancer
patient
present
symptom
patient
sever
diseas
exampl
pneumonia
critic
ill
may
panel
broaden
includ
hmpv
adenoviru
even
virus
rare
caus
lrti
like
rhinoviru
coronaviru
howev
evid
approach
low
strongli
advis
defin
local
guidelin
topic
kept
mind
herpesvirida
caus
crv
infect
therefor
rational
look
cytomegaloviru
epsteinebarr
viru
herp
simplex
viru
varicella
zoster
patient
typic
symptom
crv
infect
patient
symptom
lrti
essenti
determin
degre
pulmonari
involv
crv
affect
tracheobronchi
system
lung
parenchyma
gener
chest
xray
proven
unhelp
diagnos
patholog
chang
set
lack
sensit
therefor
recommend
ii
see
tabl
contrast
good
evid
recommend
ct
scan
chest
detect
lrti
patient
crv
infect
ii
see
tabl
bronchial
wall
thicken
well
interstiti
infiltr
present
groundglass
opac
may
detect
defin
increas
lung
densiti
wherea
underli
lung
architectur
still
detect
groundglass
opac
may
patchi
diffus
well
distinguish
consolid
show
higher
densiti
obscur
eg
pulmonari
vessel
typic
differenti
diagnos
includ
bacteri
infect
affect
termin
bronchiol
might
lead
visibl
usual
invis
structur
ct
small
centrilobular
nodul
treeinbud
sign
evid
bronchiol
caus
airtrap
reliabl
detect
airtrap
inspiratori
ct
normal
ct
scan
expir
necessari
addit
good
diagnost
accuraci
regard
diagnosi
viral
lrti
ct
scan
may
also
reveal
evid
outbreak
sinc
specif
virus
tend
present
typic
pattern
ct
scan
exampl
see
fig
light
danger
outbreak
fatal
consequ
import
measur
manag
cancer
patient
crv
infect
infect
control
tabl
local
author
give
exact
guidanc
necessari
precaut
respect
institut
follow
statement
intend
give
gener
overview
suffici
evid
recommend
stringent
hand
hygien
iit
use
face
mask
b
iit
contact
isol
iii
tabl
importantli
shed
crv
cancer
patient
often
last
week
longer
therefor
wise
perform
followup
test
respiratori
materi
index
patient
stop
contact
isol
becam
neg
note
earli
implement
infect
control
appear
effect
late
implement
give
reason
recommend
infect
control
soon
symptom
appear
evid
crv
almost
anybodi
catch
cold
appli
form
home
remedi
convinc
eas
symptom
posit
influenc
cours
diseas
contrast
widespread
use
littl
evid
recommend
measur
particular
regard
cancer
patient
evid
poor
give
sound
recommend
favour
use
vitamin
c
echinacea
garlic
zinc
humidifi
hot
air
chines
herbal
medicin
surprisingli
even
painkil
nonsteroid
antiinflammatori
drug
may
eas
pain
littl
influenc
sever
durat
crv
infect
howev
evid
toward
consider
placebo
effect
argu
patient
allow
continu
home
remedi
provid
reason
assum
harm
may
case
chines
herbal
medicin
contamin
heavi
metal
possibl
contract
invas
fungal
infect
inhal
contamin
air
needless
say
littl
gain
treat
viral
infect
antibiot
also
true
cancer
patient
iir
treat
viral
infect
antibiot
howev
mind
high
rate
superinfect
cancer
patient
viral
lrti
suspect
proven
bacterialfung
coinfect
treat
accordingli
iii
cancer
patient
present
symptom
consist
crv
infect
prior
initi
chemotherapi
delay
treatment
consid
sinc
retrospect
studi
group
show
benefit
treatment
delay
patient
undergo
allosct
clearli
recommend
delay
condit
patient
schedul
allosct
evid
crv
infect
ii
see
tabl
situat
less
clear
patient
less
aggress
treatment
sinc
report
unev
cours
even
highdos
chemotherapi
patient
initi
crv
infect
therefor
recommend
delay
chemotherapi
possibl
safe
side
mere
weak
one
tabl
groundglass
opac
found
patchi
charact
fig
often
combin
centrilobular
nodul
treeinbud
fig
case
nodul
groundglass
charact
detect
fig
rsv
respiratori
syncyti
viru
similarli
reduc
immunosuppress
patient
lrti
due
adenovirusinfect
allosct
well
found
retrospect
cohort
studi
group
thu
clearli
recommend
ii
tabl
data
transfer
situat
lrti
caus
crv
therefor
reduct
immunosuppress
also
recommend
allosct
recipi
lrti
caus
crv
iit
tabl
contrast
situat
less
clear
patient
urti
therefor
weak
recommend
made
c
iii
tabl
regard
support
applic
system
medic
antivir
recommend
made
use
steroid
sinc
show
effect
prolong
viral
shed
iii
tabl
contrast
intraven
immunoglobulin
ivig
therapeut
option
rsv
infect
b
iii
may
also
benefici
influenza
piv
hmpv
infect
c
iii
tabl
lack
data
recommend
made
regard
use
ivig
crv
infect
causal
treatment
deem
necessari
influenza
tradit
treat
amantadin
rimantadin
nowaday
resist
rate
high
neither
recommend
ii
contrast
despit
ongo
discuss
regard
balanc
efficaci
side
effect
treatment
choic
appear
neuraminidas
inhibitor
oseltamivir
zanamivir
peramivir
recommend
prophylaxi
well
treatment
exampl
http
wwwrkide
decontentinfaziinfluenzaipvipvnodehtml
howev
data
regard
efficaci
prophylact
use
neuraminidas
inhibitor
cancer
patient
weak
almost
exclus
set
stem
cell
transplant
therefor
author
believ
justifi
give
recommend
favour
use
cancer
patient
gener
thu
prevent
influenza
applic
neuraminidas
inhibitor
remain
one
unresolv
issu
requir
studi
still
includ
inform
dose
durat
tabl
treatment
influenza
usual
recommend
symptomat
patient
high
risk
prefer
onset
symptom
cancer
patient
might
regard
highrisk
patient
per
se
neuraminidas
inhibitor
usual
oseltamivir
often
routin
given
patient
malign
influenza
sinc
mostli
retrospect
data
show
benefit
earli
antivir
treatment
regard
develop
lrti
complic
thu
recommend
use
oseltamivir
zanamivir
b
ii
tabl
evid
recommend
earli
initi
treatment
necessarili
mean
later
treatment
futil
therefor
mani
author
recommend
treatment
regardless
timepoint
howev
think
either
dose
mgd
durat
longer
well
defin
avail
evid
need
determin
local
specialist
reason
usual
given
higher
dose
longer
treatment
durat
highrisk
patient
prolong
viral
shed
observ
cancer
patient
thu
deduc
suscept
develop
resist
treat
effect
peramivir
receiv
fda
approv
pandem
recommend
patient
infect
unabl
take
oral
medic
avail
germani
includ
guidelin
sake
complet
tabl
author
advis
use
sever
case
oral
intak
inhal
possibl
ciii
anoth
salvag
option
may
combin
zanamivir
oseltamivir
ribavirin
sinc
shown
efficaci
older
studi
rsv
usual
treat
intraven
immunoglobulin
ivig
b
iii
tabl
ribavirin
europ
monoclon
antibodi
palivizumab
licens
prevent
rsv
children
addit
benefit
polyclon
ivig
entir
conclus
reason
make
clear
recommend
use
cancer
patient
sinc
regard
tabl
recommend
regard
causal
treatment
influenza
rsv
parainfluenza
adenoviru
question
whether
use
palivizumab
instead
ivig
unresolv
question
requir
studi
ribavirin
agent
choic
treatment
rsv
infect
avail
data
concern
allosct
recipi
recent
evid
also
suggest
benefit
less
sever
immunosuppress
cancer
patient
appear
lower
progress
rate
lrti
report
posit
influenc
surviv
howev
author
report
favour
outcom
rsv
infect
without
causal
treatment
tradit
use
aerosol
see
tabl
applic
mode
cumbersom
may
associ
teratogen
effect
also
patient
may
abl
inhal
long
time
may
react
bronchospasm
thu
oral
applic
use
increasingli
similar
efficaci
even
intraven
applic
report
despit
report
good
outcom
without
treatment
believ
avail
evid
justifi
recommend
use
ribavirin
cancer
patient
rsv
infect
b
ii
tabl
also
least
highrisk
patient
treatment
given
stage
urti
sinc
shown
benefit
b
ii
experi
antivir
therapi
gener
ribavirin
patient
parainfluenza
infect
larg
efficaci
entir
convinc
may
partli
causal
treatment
start
late
cours
diseas
partli
caus
death
often
coinfect
requir
antibiot
therapi
nonetheless
may
reason
attempt
therapi
ribavirin
patient
parainfluenza
infect
c
iii
tabl
causal
therapi
cidofovir
justifi
immunosuppress
cancer
patient
lrti
caus
adenoviru
b
ii
tabl
experiment
therapi
employ
set
allosct
includ
donorlymphocyt
infus
adapt
transfer
specif
tcell
howev
date
evid
weak
justifi
recommend
favour
use
treatment
modal
causal
therapi
ribavirin
attempt
patient
infect
caus
hmpv
albeit
unconvinc
result
enough
evid
make
definit
recommend
use
specif
antivir
drug
causal
treatment
approach
like
interferon
crv
one
discuss
earli
diagnosi
gener
infect
prevent
may
improv
outcom
cancer
patient
crv
infect
despit
data
regard
virus
influenza
rsv
patient
popul
hsctrecipi
still
lack
inform
crv
patient
popul
exampl
solid
tumour
also
almost
prospect
randomis
trial
perform
treatment
crv
infect
cancer
patient
thu
recommend
deduc
popul
studi
urgent
need
none
travel
expens
cost
group
meet
reimburs
german
societi
haematolog
medic
oncolog
mvlt
receiv
honoraria
travel
support
gilead
msd
pfizer
celgen
janssen
cilag
receiv
travel
support
astella
pharma
receiv
research
support
msd
member
advisori
board
msd
mc
receiv
research
fund
deutsch
forschungsgemeinschaft
dfg
erich
und
gertrud
roggenbuck
stiftung
speaker
msd
basilea
consult
msd
basilea
receiv
travel
grant
celgen
takeda
gilead
msd
recipi
msd
stipend
oncolog
mh
serv
advisori
board
gilead
roch
pharma
takeda
serv
speaker
bureau
celgen
novarti
janssen
amgen
cph
stock
owner
stada
gsk
receiv
consult
fee
andor
honoraria
scheringplough
pfizer
basilea
boehring
ingelheim
novarti
roch
astella
gilead
msd
lilli
intermun
freseniu
olympu
gilead
astrazeneca
bracco
meda
pharma
chiesi
siemen
covidien
pierr
fabr
grifol
research
fund
siemen
pfizer
mevi
boehring
ingelheim
mk
receiv
honoraria
travel
support
serv
speaker
bureau
gilead
msd
pfizer
op
receiv
honoraria
travel
support
astella
gilead
jazz
msd
neovii
biotech
pfizer
receiv
research
support
bio
rad
gilead
jazz
neovii
biotech
pierr
fabr
sanofi
takeda
member
advisori
board
alexion
jazz
gilead
msd
mjgtv
consult
berlin
chemi
msdmerck
astella
pharma
serv
speaker
bureau
pfizer
merckmsd
gilead
scienc
organobal
astella
pharma
receiv
research
fund
astella
pharma
davolterra
gilead
scienc
gs
receiv
grantresearch
support
msd
sharp
dohm
gmbh
haar
germani
pfizer
berlin
germani
gilead
scienc
martinsri
germani
astella
pharma
gmbh
nchen
germani
serv
consult
msd
sharp
dohm
gmbh
haar
germani
basilea
pharmaceut
internatio
ltd
switzerland
remain
author
declar
conflict
interest
